Cargando…

Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study

OBJECTIVES: To determine the relationship between manufacturer-related financial ties among investigators of published drug trials and rates of discrepant registered and published primary trial outcomes. DESIGN: Cross-sectional study. SETTING: Human subjects drug trials published in ‘core clinical’...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Christopher W, Misemer, Benjamin S, Platts-Mills, Timothy F, Ahn, Rosa, Woodbridge, Alexandra, Abraham, Ann, Saba, Susan, Korenstein, Deborah, Madden, Erin, Keyhani, Salomeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829948/
https://www.ncbi.nlm.nih.gov/pubmed/29439079
http://dx.doi.org/10.1136/bmjopen-2017-019831
_version_ 1783302920468430848
author Jones, Christopher W
Misemer, Benjamin S
Platts-Mills, Timothy F
Ahn, Rosa
Woodbridge, Alexandra
Abraham, Ann
Saba, Susan
Korenstein, Deborah
Madden, Erin
Keyhani, Salomeh
author_facet Jones, Christopher W
Misemer, Benjamin S
Platts-Mills, Timothy F
Ahn, Rosa
Woodbridge, Alexandra
Abraham, Ann
Saba, Susan
Korenstein, Deborah
Madden, Erin
Keyhani, Salomeh
author_sort Jones, Christopher W
collection PubMed
description OBJECTIVES: To determine the relationship between manufacturer-related financial ties among investigators of published drug trials and rates of discrepant registered and published primary trial outcomes. DESIGN: Cross-sectional study. SETTING: Human subjects drug trials published in ‘core clinical’ MEDLINE journals in 2013. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary study endpoint was the presence of a prospectively registered, clearly defined primary outcome that matched the published primary outcome for each included trial. Secondary outcomes included assessments of registration timing and quality, and the impact of outcome discrepancies between registration and publication on the statistical significance of the included trials. RESULTS: Of 192 included trials, 134 (70%) were positive and 58 (30%) were negative. Financial ties were present between first or last authors and drug manufacturers for 130 trials (68%), of which 78% were positive, versus 53% of trials with no financial ties that were positive. Clearly defined, prospectively registered outcomes that matched the published outcomes were present in just 76 of the 192 trials (40%). After adjusting for study start date and sample size, the observed relationship between investigator financial ties and the presence of a match between prospectively registered and published primary outcomes was of borderline statistical significance (OR 2.12, 95% CI 0.998 to 4.50). Studies with financial ties present were more likely than studies without ties to have been prospectively registered (78%vs48%, P<0.001) and were more likely to have prospectively registered a clearly defined primary outcome(62%vs35%, P<0.001). CONCLUSIONS: Less than half of the trials in this cohort were prospectively registered with a clear primary outcome that was consistent with the primary outcome reported in the published manuscript. The presence of investigator financial ties was associated with higher quality registration practices, though this association diminished after adjusting for factors that impact registration quality.
format Online
Article
Text
id pubmed-5829948
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-58299482018-03-01 Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study Jones, Christopher W Misemer, Benjamin S Platts-Mills, Timothy F Ahn, Rosa Woodbridge, Alexandra Abraham, Ann Saba, Susan Korenstein, Deborah Madden, Erin Keyhani, Salomeh BMJ Open Medical Publishing and Peer Review OBJECTIVES: To determine the relationship between manufacturer-related financial ties among investigators of published drug trials and rates of discrepant registered and published primary trial outcomes. DESIGN: Cross-sectional study. SETTING: Human subjects drug trials published in ‘core clinical’ MEDLINE journals in 2013. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary study endpoint was the presence of a prospectively registered, clearly defined primary outcome that matched the published primary outcome for each included trial. Secondary outcomes included assessments of registration timing and quality, and the impact of outcome discrepancies between registration and publication on the statistical significance of the included trials. RESULTS: Of 192 included trials, 134 (70%) were positive and 58 (30%) were negative. Financial ties were present between first or last authors and drug manufacturers for 130 trials (68%), of which 78% were positive, versus 53% of trials with no financial ties that were positive. Clearly defined, prospectively registered outcomes that matched the published outcomes were present in just 76 of the 192 trials (40%). After adjusting for study start date and sample size, the observed relationship between investigator financial ties and the presence of a match between prospectively registered and published primary outcomes was of borderline statistical significance (OR 2.12, 95% CI 0.998 to 4.50). Studies with financial ties present were more likely than studies without ties to have been prospectively registered (78%vs48%, P<0.001) and were more likely to have prospectively registered a clearly defined primary outcome(62%vs35%, P<0.001). CONCLUSIONS: Less than half of the trials in this cohort were prospectively registered with a clear primary outcome that was consistent with the primary outcome reported in the published manuscript. The presence of investigator financial ties was associated with higher quality registration practices, though this association diminished after adjusting for factors that impact registration quality. BMJ Publishing Group 2018-02-08 /pmc/articles/PMC5829948/ /pubmed/29439079 http://dx.doi.org/10.1136/bmjopen-2017-019831 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Medical Publishing and Peer Review
Jones, Christopher W
Misemer, Benjamin S
Platts-Mills, Timothy F
Ahn, Rosa
Woodbridge, Alexandra
Abraham, Ann
Saba, Susan
Korenstein, Deborah
Madden, Erin
Keyhani, Salomeh
Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study
title Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study
title_full Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study
title_fullStr Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study
title_full_unstemmed Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study
title_short Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study
title_sort primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study
topic Medical Publishing and Peer Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829948/
https://www.ncbi.nlm.nih.gov/pubmed/29439079
http://dx.doi.org/10.1136/bmjopen-2017-019831
work_keys_str_mv AT joneschristopherw primaryoutcomeswitchingamongdrugtrialswithandwithoutprincipalinvestigatorfinancialtiestoindustryacrosssectionalstudy
AT misemerbenjamins primaryoutcomeswitchingamongdrugtrialswithandwithoutprincipalinvestigatorfinancialtiestoindustryacrosssectionalstudy
AT plattsmillstimothyf primaryoutcomeswitchingamongdrugtrialswithandwithoutprincipalinvestigatorfinancialtiestoindustryacrosssectionalstudy
AT ahnrosa primaryoutcomeswitchingamongdrugtrialswithandwithoutprincipalinvestigatorfinancialtiestoindustryacrosssectionalstudy
AT woodbridgealexandra primaryoutcomeswitchingamongdrugtrialswithandwithoutprincipalinvestigatorfinancialtiestoindustryacrosssectionalstudy
AT abrahamann primaryoutcomeswitchingamongdrugtrialswithandwithoutprincipalinvestigatorfinancialtiestoindustryacrosssectionalstudy
AT sabasusan primaryoutcomeswitchingamongdrugtrialswithandwithoutprincipalinvestigatorfinancialtiestoindustryacrosssectionalstudy
AT korensteindeborah primaryoutcomeswitchingamongdrugtrialswithandwithoutprincipalinvestigatorfinancialtiestoindustryacrosssectionalstudy
AT maddenerin primaryoutcomeswitchingamongdrugtrialswithandwithoutprincipalinvestigatorfinancialtiestoindustryacrosssectionalstudy
AT keyhanisalomeh primaryoutcomeswitchingamongdrugtrialswithandwithoutprincipalinvestigatorfinancialtiestoindustryacrosssectionalstudy